Fractionated radioimmunotherapy of B-cell malignancies with131I-lym-1

Gerald L Denardo, Sally J. DeNardo, Lois F. O'Grady, Norman B. Levy, Gregory P. Adams, Stanley L. Mills

Research output: Contribution to journalArticle

134 Citations (Scopus)

Abstract

Eighteen patients with Stage 4 B-cell malignancies, which were primarily of intermediate or high grade and progressive despite multiple drug chemotherapy and external irradiation, were treated with fractionated doses of 131I-labeled Lym-1. Lym-1 is an IgG2a monoclonal antibody that was produced by immunizing mice with Raji cell nuclei that originated from a patient with African Burkitt's lymphoma. Despite advanced disease, 10 of the patients had objective evidence for a complete or partial remission. Toxicity was very modest except in one patient who developed hypotension. Dose-dependent hepatic uptake of Lym-1 was observed in the patients and in BALB/c mice suggesting receptor-mediated recognition of this murine antibody.

Original languageEnglish (US)
JournalCancer Research
Volume50
Issue number3 SUPPL.
StatePublished - 1990

Fingerprint

Radioimmunotherapy
B-Lymphocytes
Burkitt Lymphoma
Neoplasms
Cell Nucleus
Hypotension
Monoclonal Antibodies
Drug Therapy
Antibodies
Liver
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Denardo, G. L., DeNardo, S. J., O'Grady, L. F., Levy, N. B., Adams, G. P., & Mills, S. L. (1990). Fractionated radioimmunotherapy of B-cell malignancies with131I-lym-1. Cancer Research, 50(3 SUPPL.).

Fractionated radioimmunotherapy of B-cell malignancies with131I-lym-1. / Denardo, Gerald L; DeNardo, Sally J.; O'Grady, Lois F.; Levy, Norman B.; Adams, Gregory P.; Mills, Stanley L.

In: Cancer Research, Vol. 50, No. 3 SUPPL., 1990.

Research output: Contribution to journalArticle

Denardo, GL, DeNardo, SJ, O'Grady, LF, Levy, NB, Adams, GP & Mills, SL 1990, 'Fractionated radioimmunotherapy of B-cell malignancies with131I-lym-1', Cancer Research, vol. 50, no. 3 SUPPL..
Denardo GL, DeNardo SJ, O'Grady LF, Levy NB, Adams GP, Mills SL. Fractionated radioimmunotherapy of B-cell malignancies with131I-lym-1. Cancer Research. 1990;50(3 SUPPL.).
Denardo, Gerald L ; DeNardo, Sally J. ; O'Grady, Lois F. ; Levy, Norman B. ; Adams, Gregory P. ; Mills, Stanley L. / Fractionated radioimmunotherapy of B-cell malignancies with131I-lym-1. In: Cancer Research. 1990 ; Vol. 50, No. 3 SUPPL.
@article{d217dd03645a457dbb1acf0a57f3cb1c,
title = "Fractionated radioimmunotherapy of B-cell malignancies with131I-lym-1",
abstract = "Eighteen patients with Stage 4 B-cell malignancies, which were primarily of intermediate or high grade and progressive despite multiple drug chemotherapy and external irradiation, were treated with fractionated doses of 131I-labeled Lym-1. Lym-1 is an IgG2a monoclonal antibody that was produced by immunizing mice with Raji cell nuclei that originated from a patient with African Burkitt's lymphoma. Despite advanced disease, 10 of the patients had objective evidence for a complete or partial remission. Toxicity was very modest except in one patient who developed hypotension. Dose-dependent hepatic uptake of Lym-1 was observed in the patients and in BALB/c mice suggesting receptor-mediated recognition of this murine antibody.",
author = "Denardo, {Gerald L} and DeNardo, {Sally J.} and O'Grady, {Lois F.} and Levy, {Norman B.} and Adams, {Gregory P.} and Mills, {Stanley L.}",
year = "1990",
language = "English (US)",
volume = "50",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "3 SUPPL.",

}

TY - JOUR

T1 - Fractionated radioimmunotherapy of B-cell malignancies with131I-lym-1

AU - Denardo, Gerald L

AU - DeNardo, Sally J.

AU - O'Grady, Lois F.

AU - Levy, Norman B.

AU - Adams, Gregory P.

AU - Mills, Stanley L.

PY - 1990

Y1 - 1990

N2 - Eighteen patients with Stage 4 B-cell malignancies, which were primarily of intermediate or high grade and progressive despite multiple drug chemotherapy and external irradiation, were treated with fractionated doses of 131I-labeled Lym-1. Lym-1 is an IgG2a monoclonal antibody that was produced by immunizing mice with Raji cell nuclei that originated from a patient with African Burkitt's lymphoma. Despite advanced disease, 10 of the patients had objective evidence for a complete or partial remission. Toxicity was very modest except in one patient who developed hypotension. Dose-dependent hepatic uptake of Lym-1 was observed in the patients and in BALB/c mice suggesting receptor-mediated recognition of this murine antibody.

AB - Eighteen patients with Stage 4 B-cell malignancies, which were primarily of intermediate or high grade and progressive despite multiple drug chemotherapy and external irradiation, were treated with fractionated doses of 131I-labeled Lym-1. Lym-1 is an IgG2a monoclonal antibody that was produced by immunizing mice with Raji cell nuclei that originated from a patient with African Burkitt's lymphoma. Despite advanced disease, 10 of the patients had objective evidence for a complete or partial remission. Toxicity was very modest except in one patient who developed hypotension. Dose-dependent hepatic uptake of Lym-1 was observed in the patients and in BALB/c mice suggesting receptor-mediated recognition of this murine antibody.

UR - http://www.scopus.com/inward/record.url?scp=0025120319&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025120319&partnerID=8YFLogxK

M3 - Article

C2 - 2297713

AN - SCOPUS:0025120319

VL - 50

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 3 SUPPL.

ER -